

## Special Issue

# Advances in Drug Development for Skin Cancer

### Message from the Guest Editor

Skin cancers are the most common type of cancers worldwide. Although surgical treatment is often curative for skin cancer, topical and/or systemic agents are often necessary as well. The past decade has seen a rapid increase in the number and types of treatments available for treatment of skin cancers, with many more agents under development. Here, we are interested in both novel agents and treatment strategies for skin cancers (both melanomas and non-melanoma skin cancers). Articles of interest will thus span both novel agents in development and the repurposing of other agents that can be utilized towards skin cancer treatment or prevention. Of special interest are advances that deal with immune modulation for treatment of skin cancer, though studies focusing on targeted agents are also welcomed. We are interested in all aspects of drug development, from pre-clinical and in vitro studies to clinical studies, including mechanistic studies. We also welcome articles that discuss side effects from treatments for skin cancer and potential strategies to mitigate them.

### Guest Editor

Dr. Rajan P. Kulkarni

Department of Dermatology, Oregon Health & Science University,  
Portland, OR 97239, USA

### Deadline for manuscript submissions

closed (31 March 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/152835](https://mdpi.com/si/152835)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)